

Richard Donnelly

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3221285/publications.pdf>

Version: 2024-02-01

47
papers

1,451
citations

471509

17
h-index

330143

37
g-index

118
all docs

118
docs citations

118
times ranked

2251
citing authors

#	ARTICLE	IF	CITATIONS
1	Blood markers in remote ischaemic conditioning for acute ischaemic stroke: data from the REremote ischaemic Conditioning After Stroke Trial. <i>European Journal of Neurology</i> , 2021, 28, 1225-1233.	3.3	4
2	The relationship between urinary albumin excretion, cardiovascular outcomes and total mortality among a large cohort of insulin-treated patients with type 2 diabetes in routine primary care practices. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 471-477.	0.7	2
3	Sex Hormone-Binding Globulin (SHBG) as an Early Biomarker and Therapeutic Target in Polycystic Ovary Syndrome. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8191.	4.1	74
4	Effect of Bariatric Surgery on Diagnosed Chronic Kidney Disease and Cardiovascular Events in Patients with Insulin-treated Type 2 Diabetes: a Retrospective Cohort Study from a Large UK Primary Care Database. <i>Obesity Surgery</i> , 2020, 30, 1685-1695.	2.1	6
5	Effect of Bariatric Surgery on Cardiovascular Events and Metabolic Outcomes in Obese Patients with Insulin-Treated Type 2 Diabetes: a Retrospective Cohort Study. <i>Obesity Surgery</i> , 2019, 29, 3154-3164.	2.1	14
6	Albuminuria Regression and All-Cause Mortality among Insulin-Treated Patients with Type 2 Diabetes: Analysis of a Large UK Primary Care Cohort. <i>American Journal of Nephrology</i> , 2019, 49, 146-155.	3.1	16
7	Individual and Combined Relationship between Reduced eGFR and/or Increased Urinary Albumin Excretion Rate with Mortality Risk among Insulin-Treated Patients with Type 2 Diabetes in Routine Practice. <i>Kidney Diseases (Basel, Switzerland)</i> , 2019, 5, 91-99.	2.5	5
8	Tier 3 specialist weight management service and pre-bariatric multicomponent weight management programmes for adults with obesity living in the UK: A systematic review. <i>Endocrinology, Diabetes and Metabolism</i> , 2019, 2, e00042.	2.4	21
9	Efficacy and Safety of Pioglitazone Monotherapy in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. <i>Scientific Reports</i> , 2019, 9, 5389.	3.3	64
10	Relationship between HbA1c and all-cause mortality in older patients with insulin-treated type 2 diabetes: results of a large UK Cohort Study. <i>Age and Ageing</i> , 2019, 48, 235-240.	1.6	11
11	Effects of obesity on metabolic and cardiovascular outcomes following insulin initiation in patients with type 2 diabetes. <i>Obesity Research and Clinical Practice</i> , 2018, 12, 72-84.	1.8	6
12	Effect of adding GLP-1RA on mortality, cardiovascular events, and metabolic outcomes among insulin-treated patients with type 2 diabetes: A large retrospective UK cohort study. <i>American Heart Journal</i> , 2018, 196, 18-27.	2.7	15
13	Association between insulin-induced weight change and CVD mortality: Evidence from a historic cohort study of 18,814 patients in UK primary care. <i>Diabetes/Metabolism Research and Reviews</i> , 2018, 34, e2945.	4.0	6
14	RECAST (Remote Ischemic Conditioning After Stroke Trial). <i>Stroke</i> , 2017, 48, 1412-1415.	2.0	131
15	Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: a Bayesian meta-analysis of survival data. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 329-335.	4.4	104
16	Effects of background statin therapy on glycaemic response and cardiovascular events following initiation of insulin therapy in type 2 diabetes: a large UK cohort study. <i>Cardiovascular Diabetology</i> , 2017, 16, 107.	6.8	11
17	Drug-Induced Diabetes Mellitus: Evidence for Statins and Other Drugs Affecting Glucose Metabolism. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 99, 390-400.	4.7	30
18	Cardiovascular events and all-cause mortality with insulin versus glucagon-like peptide-1 analogue in type 2 diabetes. <i>Heart</i> , 2016, 102, 1581-1587.	2.9	29

#	ARTICLE	IF	CITATIONS
19	Comparison of cardiovascular and metabolic outcomes in people with type 2 diabetes on insulin versus non-insulin glucose-lowering therapies (GLTs): A systematic review and meta-analysis of clinical trials. <i>Diabetes Research and Clinical Practice</i> , 2016, 121, 69-85.	2.8	13
20	Effect of diabetes on the cutaneous microcirculation of the feet in patients with intermittent claudication. <i>Clinical Hemorheology and Microcirculation</i> , 2016, 61, 439-444.	1.7	15
21	Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study. <i>Annals of Medicine</i> , 2016, 48, 224-234.	3.8	36
22	Determinants of Glycemic Response to Add-On Therapy with a Dipeptidyl Peptidase-4 Inhibitor: A Retrospective Cohort Study Using a United Kingdom Primary Care Database. <i>Diabetes Technology and Therapeutics</i> , 2016, 18, 85-92.	4.4	7
23	Comparative Efficacy of Adding Sitagliptin to Metformin, Sulfonylurea or Dual Therapy: A Propensity Score-Weighted Cohort Study. <i>Diabetes Therapy</i> , 2015, 6, 213-226.	2.5	4
24	Canagliflozin: SGLT2 inhibitor for treating type 2 diabetes. <i>Future Prescriber</i> , 2013, 14, 5-7.	0.1	1
25	Association Between Thiazolidinedione Treatment and Risk of Macular Edema Among Patients With Type 2 Diabetes. <i>Archives of Internal Medicine</i> , 2012, 172, 1005-11.	3.8	70
26	Review: Angiotensin-converting enzyme inhibitors and coronary heart disease prevention. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2007, 8, 13-22.	1.7	18
27	Type 2 diabetes in China: partnerships in education and research to evaluate new antidiabetic treatments. <i>British Journal of Clinical Pharmacology</i> , 2006, 61, 702-705.	2.4	17
28	Rising impact of Diabetes, Obesity and Metabolism. <i>Diabetes, Obesity and Metabolism</i> , 2005, 7, 1-1.	4.4	4
29	ACE inhibitors and cardiovascular protection in diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2004, 6, 399-401.	4.4	0
30	Microalbuminuria: a common, independent cardiovascular risk factor, especially but not exclusively in type 2 diabetes. <i>Journal of Hypertension Supplement: Official Journal of the International Society of Hypertension</i> , 2003, 21, S7-12.	0.1	22
31	Therapeutic angiogenesis: a step forward in intermittent claudication. <i>Lancet, The</i> , 2002, 359, 2048-2050.	13.7	22
32	Evidence-based symptom relief of intermittent claudication: efficacy and safety of cilostazol. <i>Diabetes, Obesity and Metabolism</i> , 2002, 4, S20-S25.	4.4	8
33	Insulin Action in Skeletal Muscle. <i>Annals of the New York Academy of Sciences</i> , 2002, 967, 176-182.	3.8	13
34	Clinical Pharmacokinetics of Inhaled Budesonide. <i>Clinical Pharmacokinetics</i> , 2001, 40, 427-440.	3.5	43
35	Acute hyperhomocysteinaemia affects pulse pressure but not microvascular vasodilator function. <i>British Journal of Clinical Pharmacology</i> , 2001, 52, 327-332.	2.4	14
36	Vascular complications in type 2 diabetes: current perspectives. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2001, 18, S19-S24.	0.2	1

#	ARTICLE	IF	CITATIONS
37	Effects of tumour necrosis factor- α and inhibition of protein kinase C on glucose uptake in L6 myoblasts. <i>Clinical Science</i> , 2000, 99, 303-307.	4.3	14
38	Type 2 diabetes and atherosclerosis. <i>Diabetes, Obesity and Metabolism</i> , 2000, 2, S21-S30.	4.4	15
39	HOPE for diabetes in the new millennium. <i>Diabetes, Obesity and Metabolism</i> , 2000, 2, 1-2.	4.4	19
40	The UK Prospective Diabetes Study (UKPDS): clinical and therapeutic implications for type 2 diabetes. <i>British Journal of Clinical Pharmacology</i> , 1999, 48, 643-648.	2.4	436
41	Exciting times for pharmacological research in diabetes, obesity and metabolism. <i>Diabetes, Obesity and Metabolism</i> , 1999, 1, 1-1.	4.4	10
42	FDA reviews troglitazone. <i>Diabetes, Obesity and Metabolism</i> , 1999, 1, 65-66.	4.4	5
43	Clinical Implications of Indapamide Sustained Release 1.5mg in Hypertension. <i>Clinical Pharmacokinetics</i> , 1999, 37, 21-32.	3.5	9
44	MECHANISMS OF INSULIN RESISTANCE AND NEW PHARMACOLOGICAL APPROACHES TO METABOLISM AND DIABETIC COMPLICATIONS. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1998, 25, 79-87.	1.9	29
45	METABOLIC EFFECTS OF THIOCTIC ACID IN RODENT MODELS OF INSULIN RESISTANCE AND DIABETES. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1998, 25, 712-714.	1.9	8
46	Is There a Concentration-Effect Relationship for Sulphonylureas?. <i>Clinical Pharmacokinetics</i> , 1998, 34, 181-188.	3.5	24
47	Diabetes and Peripheral Arterial Disease. , 0, , 199-222.		0